Johnson & Johnson’s (NYSE:JNJ) DePuy Synthes announced that it acquired CrossRoads Extremity Systems.
Tennessee-based CrossRoads Extremity Systems develops a range of procedure-specific, sterile-packed implants and instrumentation systems cleared for lower extremity indications. The company grew into a leader in the foot and ankle space with backing from HealthpointCapital.
According to a news release, in acquiring CrossRoads, DePuy Synthes adds a number of differentiated products to its portfolio, including the miniBunion 3D, dynaBunion 4D and DynaFoce staple compression plates.
CrossRoads designed miniBunion as a minimally invasive solution for metatarsal bone osteotomy, while it developed the dynaBunion lapidus system as an option for lapidus bunionectomy and a provider of instrumentation and implants to correct bunions in four dimensions through smaller incisions.
DynaForce staple compression plates combine stability with dynamic continuous compression at the fusion site, DePuy Synthes said, with the combination of the three systems offering surgical options for addressing a wide array of bunion deformities from mild to severe.
The CrossRoads portfolio has more than 25 products overall, including the EcoSmart instrument service that provides sterilized, reusable instruments for surgical cases, as well as post-surgery instrument recovery and processing to reduce waste and inefficiencies in the operating room.
“At DePuy Synthes, we look at innovation with one goal in mind: to bring differentiated solutions to market to address the unmet needs of surgeons and patients around the world,” DePuy Synthes Trauma, Extremities, Craniomaxillofacial and Animal Health Worldwide President Oray Boston said in the release. “Healthy feet are a foundational element of overall good health, and we are thrilled about the acquisition of CrossRoads and the opportunity to accelerate meaningful innovation by strengthening our offering for elective foot and ankle procedures, enabling us to provide more comprehensive and leading-edge options to surgeons and patients.”
Financial terms for the acquisition were not disclosed.